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Abstract: Marine fungi are known to produce structurally unique secondary metabolites, 
and more than 1000 marine fungal-derived metabolites have already been reported. Despite 
the absence of marine fungal-derived metabolites in the current clinical pipeline, dozens of 
them have been classified as potential chemotherapy candidates because of their anticancer 
activity. Over the last decade, several comprehensive reviews have covered the potential 
anticancer activity of marine fungal-derived metabolites. However, these reviews consider 
the term “cytotoxicity” to be synonymous with “anticancer agent”, which is not actually 
true. Indeed, a cytotoxic compound is by definition a poisonous compound. To become a 
potential anticancer agent, a cytotoxic compound must at least display (i) selectivity 
between normal and cancer cells (ii) activity against multidrug-resistant (MDR) cancer 
cells; and (iii) a preferentially non-apoptotic cell death mechanism, as it is now well known 
that a high proportion of cancer cells that resist chemotherapy are in fact apoptosis-resistant 
cancer cells against which pro-apoptotic drugs have more than limited efficacy. The 
present review thus focuses on the cytotoxic marine fungal-derived metabolites whose 
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ability to kill cancer cells has been reported in the literature. Particular attention is paid to 
the compounds that kill cancer cells through non-apoptotic cell death mechanisms. 
Keywords: marine fungi; natural products; anticancer; chemotherapeutic; cytotoxic; 
multidrug resistance; in vivo antitumor; non-apoptotic; pro-apoptotic; preclinical  
 
1. Introduction 
1.1. Cancer Epidemiology 
According to World Cancer Report 2014, which was published by the World Health Organization’s 
International Agency for Research on Cancer, the global incidence of cancer rose to an estimated  
14 million new cases in 2012, and this figure is expected to rise to an annual 19.3 million cases by 
2025 [1]. The same report also states that, among the commonest cancers, lung cancer was found to be 
the highest, making up 13% of the total number in 2012, followed by breast cancer (11.9%), colorectal 
cancer (9.7%), and prostate cancer (7.9%). In addition, most cancers occur in the less developed 
regions of the world, with 60% of cancers and 70% of cancer deaths occurring in Africa, Asia, and 
Central and South America. 
Torre et al. [2] argued that the occurrence of cancer is increasing because of the growth and aging 
of the population, as well as the increasing prevalence of established risk factors such as smoking, 
overweight, physical inactivity, and changing reproductive patterns associated with urbanization and 
economic development. The same authors have also reported that the other leading causes of cancer 
deaths in more developed countries included colorectal cancer among males and females and prostate 
cancer among males, whereas liver and stomach cancer among males and cervical cancer among 
females were the leading causes of cancer deaths in less developed countries [2]. 
1.2. The Role of Natural Products in Cancer Therapy 
The role of natural products in drug discovery is tremendous, specifically for the development of 
chemotherapeutic agents, and these products are the primary contributing source that feeds the current 
anticancer clinical pipeline. The contribution of natural sources is not only limited to the direct 
application of unmodified secondary metabolites but also extends to their derivatives such as  
semi-synthetic analogs of lead structures, as well as to synthetic structural mimics inspired by natural 
products. A recent survey by Newman and Giddings [3] was used to analyze the sources of the  
191 chemotherapeutic agents that were marketed from the late 1930s to the end of 2012, and this 
survey indicates that 89 can be ascribed to natural products or their modified forms, and 39 correspond 
to synthetic compounds with a natural origin, giving a total of only 63 (33%) anticancer agents that are 
classified as truly synthetic in origin. 
The large number of plant-derived anticancer drugs that are currently available clearly supports the 
leading role of terrestrial flora in cancer drug discovery, including several chemotherapeutic agents 
such as the blockbuster drug paclitaxel (Taxol®), which was originally isolated from the Pacific yew 
tree Taxus brevifolia, as well as its semi-synthetic analogs docetaxel (Taxotere®) and the third 
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generation taxane cabazitaxel (Jevtana®) [4,5]. Another successful group of plant-based antitumor 
drugs is the vinca alkaloids, namely vincristine and vinblastine, which are derived from Catharanthus 
roseus [6], the semi-synthetic camptothecin analogs irinotecan and topotecan [7,8], as well as the 
topoisomerase II inhibitors etoposide and teniposide, which are semi-synthetic derivatives of 
epipodophyllotoxin that was originally isolated from Podophyllum peltatum [9,10]. Despite their 
preponderant role in antibiotherapy, bacteria have also widely contributed to some of the most clinically 
useful drugs in the currently available chemotherapeutic arsenal. Several Streptomyces-derived active 
metabolites served as lead structures for the development of the most effective anticancer drugs such 
as the anthracyclines doxorubicin and daunomycin, as well as the mitosanes and bleomycin-related 
agents [11]. 
There is no doubt that the major class of natural product-based anticancer agents are derived 
primarily from lead compounds from the terrestrial environment, which was related to ethno-medical 
history as well as relatively easy accessibility to natural sources. However, the recognized potential of 
the marine environment as a potential resource for pharmacologically active secondary metabolites has 
led to the extensive chemical investigation of a myriad of marine organisms in recent decades, which 
has resulted in the emergence of an increasing number of candidates for the development of new 
cancer therapy drugs [12–15]. 
Despite the surprisingly vast number of new, structurally diverse, biologically active, marine-derived 
natural products, only four anticancer drugs have been developed into drugs that have been clinically 
approved by the FDA (Food and Drug Administration) or EMA (European Medicines Agency) so far. 
After receiving its FDA approval in 1969, the DNA polymerase inhibitor cytarabine was the first 
marine-derived drug that became available for clinical use. This chemotherapeutic agent is a synthetic 
analog of the nucleosides spongothymidine and spongouridine, which were extracted from the sponge 
Cryptotethya crypta in the late 1940s [16]. At present, cytarabine (Cytosar-U®) is primarily used as a 
single agent or in combination with mitoxantrone and daunorubicin to treat acute myeloid leukemia 
and for non-Hodgkin’s lymphoma and meningeal leukemia (DepoCyte®) [17]. Later, trabectedin, 
which is also known as ecteinascidin-743 (ET-743), a tetrahydroisoquinoline alkaloid originally 
isolated from the Caribbean tunicate Ecteinascidia turbinata [18,19], became clinically available in the 
EU and South Korea under the trade name Yondelis® to treat soft tissue sarcoma and relapsed 
platinum-sensitive ovarian cancer [20]. It is worth mentioning that trabectedin is now commercially 
produced by hemisynthesis from the bacterial fermentation product cyanosafracin B [21]. The third 
marine-derived chemotherapeutic agent to receive FDA and EMA approval was the tubulin inhibitor 
eribulin mesylate (Halaven®), a synthetic derivative based on the structure of the macrocyclic 
polyether halichondrin B, which was isolated in 1986 from the sponge Halichondria okadai [22]. 
Halaven® is currently used in the US, the EU and Asia to treat refractory metastatic breast cancer [23], 
and several other halichondrin B derivatives, including eribulin mesylate itself, are currently 
undergoing several clinical trials (Phase I to Phase IV) against other types of cancer [3]. Brentuximab 
vedotin is an immunoconjugate based on the fully synthetic derivative monomethyl auristatin E, and it 
was the most recent successful marine-derived anticancer drug to receive marketing authorization. 
With approval from the FDA in 2011 and the EMA in 2012, the monoclonal antibody monomethyl 
auristatin E (Adcentris®) has been used to treat Hodgkin’s and systemic anaplastic large cell 
lymphoma [24]. Dolastatin 10, the lead structure of monomethyl auristatin E, was originally reported 
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as coming from the Indian Ocean sea hare Dolabella auricularia [25], but further studies revealed that 
its metabolic sources were the cyanobacteria of the genera Simploca and Lyngbya [26,27]. 
Although marine-derived drugs are under-represented in the current chemotherapeutic clinical 
arsenal, a vast number of candidates is undergoing preclinical and advanced clinical development, 
accounting for more than 1000 clinical trials listed in both NIH (National Institutes of Health) and 
European databases [14,28]. In reference to new lead structures, new applications against other cancer 
types for the currently marketed drugs, new synthetic derivatives, as well as new regimens in 
combination with other chemotherapeutic agents, these candidates will certainly provide new clinically 
useful agents for cancer treatment in the near future. 
2. Marine Fungal-Derived Metabolites versus Cancer 
Since the development of β-lactam antibiotics, fungi have been shown to be an extremely useful 
source of lead compounds for the development of new pharmaceuticals. Further examples of  
fungal-derived therapeutic agents include top-selling drugs such as the lipid-lowering agents 
atorvastatin and simvastatin, as well as the immunosuppressive agent cyclosporine A and the 
antifungal griseofulvin, among others [29,30]. 
Fungi from terrestrial sources have provided several lead structures for the development of many 
relevant drugs that are currently used in human medicine and continue to be extensively studied. In the 
last 25 years, several research groups from pharmaceutical companies and academic institutions have 
been paying attention to marine fungi as a source of new drug leads. The recent and systematic 
chemical characterization of fungi from the marine environment has provided a total number that 
currently exceeds 1000 new natural products [31]. Although most of these metabolites are closely 
related to those isolated from their terrestrial counterparts, several examples with unusual carbon 
skeletons and substitution patterns indicate that the marine strains may possess distinct biosynthetic 
capabilities [31–33]. Despite the emergence of an impressive number of new marine fungal-derived 
metabolites with promising pharmacological activities, only the broad-spectrum antibiotic cephalosporin 
C can be tracked back as a marine fungal-derived drug so far. Cephalosporin C was discovered from a 
fungus in a sample collected from the Sardinian coast, and the fungus was later identified as 
Acremonium chrysogenum [34]. The minor contribution of fungi in marine habitats as a source of drug 
leads for the current available therapeutic arsenal is likely related to the fact that the chemical 
investigation of these organisms as producers of pharmacologically relevant metabolites was long 
neglected until the end of the 1980s, with only 15 secondary metabolites produced by marine-derived 
fungi described until 1992 [32]. 
An increasing focus on the chemical and biological potential of marine fungi and on screening for 
new lead structures with promising anticancer activities led to the identification of several relevant 
compounds. Over the last few years, several metabolites produced by marine fungi have displayed 
potent anticancer effects, which were mediated by several mechanisms such as blocking key enzymes, 
stimulating death pathways or promoting growth arrest [35].  
The current review, which covers the period from 1983 to 2014, emphasizes the direct effects of 
marine fungi-derived metabolites on the death of cancer cells. In other words, we did not review 
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marine-derived fungal metabolites merely classified as compounds that displayed potential  
anti-angiogenic effects or immunologic effects. 
2.1. Pro-Apoptotic Metabolites  
It must be emphasized that most cytotoxic cell insults will lead to apoptosis, whether the cells are 
normal or cancerous. Thus, it is mandatory to distinguish between the direct and indirect pro-apoptotic 
effects of a given compound. As explained in Sub-Section 4.1, “Are Pro-Apoptotic Compounds still 
Valuable Weapons to Combat Cancer?”, cancers that resist chemotherapy will in fact resist direct  
pro-apoptotic insults because they contain a majority of apoptosis-resistant cells as in the case of 
metastatic cancers [36–40]. 
It is worth bearing in mind that the tools available to biologists and pharmacologists studying the 
mechanisms of action of the compounds that were characterized in the late 1990s or early 2000s were 
not as sophisticated as those available today. Thus, it is still possible that some compounds that were 
described as pro-apoptotic can also display other mechanisms of action [41,42]. We will revisit this 
concept in Section 4, “How Could We Increase the Rate of Discovery of Marine-Derived Fungal 
Metabolites as Potential Anticancer Agents, at Least in Vitro?” 
The leptosins are one of the largest classes of cytotoxic fungal metabolites and so far include  
23 members, which correspond to a series of both monomeric and dimeric epipolythiodiketopiperazine 
alkaloids. These alkaloids were produced by the strain Leptosphaeria sp. OUPS-4, which was isolated 
from the brown alga Sargassum tortile collected from Tanabe Bay, Japan. All the leptosins, especially 
the dimeric members, showed cytotoxicity against the murine P388 lymphocytic cell line [43–48]. 
Leptosins M (1), F (2) and C (3) (Figure 1) revealed further anticancer effects. Leptosin M (1) 
displayed significant cytotoxicity against human cancer cell lines through the inhibition of two protein 
kinases, namely PTK and CaMKIII, and human topoisomerase II [47], and leptosins F (2) and C (3) 
are catalytic inhibitors of topoisomerase I [49]. Leptosin C (3) induced apoptosis and inhibited the Akt 
pathway [49]. The inhibition of apoptosis leads to the activation of cell survival factors (such as Akt), 
which in turn causes continuous cell proliferation in cancer tissues [50].  
 
Figure 1. Structure of leptosin M (1), F (2) and C (3). 
Leptosin M (1) Leptosin F (2) Leptosin C (3)
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A bioassay-guided fractionation of an EtOAc extract from the culture of the marine fungus 
Aspergillus versicolor KMD 901, which was isolated from a deep sea sediment collected from the 
Ulleung Basin in the East Sea of Korea, yielded a new diketopiperazine disulfide called 
deoxyapoaranotin (4), together with acetylaranotin (5) and acetylapoaranotin (6) (Figure 2) [51].  
 
Figure 2. Structures of the diketopiperazine disulfides 4–6. 
Compounds 4–6 were found to induce apoptosis in the HCT116 colon cancer cell line through both 
extrinsic and intrinsic pathways. In addition to the down-regulation of the anti-apoptotic proteins Bcl-2 
and Bcl-xL and the up-regulation of the pro-apoptotic protein Bax, they were also found to cleave 
caspases-3, -9 and -8, suggesting that the apoptotic process is initiated by caspase 8. In addition to the 
in vitro apoptotic effect, acetylapoaranotin (6), which exhibited the most potent proliferation inhibition 
effects in HCT116, AGS, A549 and MCF-7 cancer cell lines, also induced a significant inhibition of 
tumor growth in an in vivo xenograft model [51]. 
Gliotoxin (7) (Figure 3), the first member of the epipolythiodiketopiperazine class and bridged 
diketopiperazine alkaloids, has been widely reported as constituent of several marine-derived  
fungi [52–54]. Recently, Nguyen et al. [55] reported the isolation and evaluation of the anticancer 
activity of gliotoxin (7) from Aspergillus sp. strain YL-06, which was isolated from a marine brown 
alga collected in Ulsan, Korea. This compound is pro-apoptotic in human HeLa cervix carcinoma and 
SW1353 chondrosarcoma cells through the activation of caspase-3, caspase-8 and caspase-9, the 
down-regulation of Bcl-2, the  up-regulation of Bax and the release of cytochrome c (cyt c) [55]. 
 
Figure 3. Structures of gliotoxin (7) and gliotoxin derivatives 8–9. 
Gliotoxin (7) was tested for its inhibitory activity against the cytosolic metalloenzyme FTase 
(farnesyltransferase) and the related prenyltransferase GGTase I (geranylgeranyltransferase I), which 
catalyze the prenylation of several cellular proteins that are involved in tumor progression such as the 
Ras family [56]. This compound displayed a dual inhibition of FTase and GGTase I-inhibiting protein 
 
Acetylaranotin (5)Deoxyapoaranotin (4) Acetylapoaranotin (6)
 
Gliotoxin (7)      R = S2
Gliotoxin G (9)  R = S4
5a,6-Didehydrogliotoxin (8)
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isoprenylation and cell proliferation in breast cancer MCF-7 and MDA-MB-231 cell lines [57]. A 
chemical investigation of the fungus Penicillium sp. strain JMF034, which was isolated from deep sea 
sediments collected from Suruga Bay in Japan, resulted in the isolation of several gliotoxin-derived 
compounds. Gliotoxin (7) and its derivatives 5a,6-didehydrogliotoxin (8) and gliotoxin G (9) 
(Figure 3) exhibited potent inhibitory activity against the methylation regulation enzymes HMT G9a 
and HMT Set7/9 [53], which are commonly involved in the malignant transformation of cells [58]. 
The absence of activity from the other gliotoxin derivatives supported the key role of the disulfide and 
tetrasulfide bonds in the enzymatic inhibitory activity [53].  
Several new derivatives of shearinine A (10) (Figure 4), a class of janthitrem-type indole terpenes, 
were reported from the endophytic fungus Penicillium sp. strain HKI0459, which was isolated from a 
mangrove plant collected near Xianen City, China [59]. At the same time, Smetanina et al. [60] 
reported the isolation of two additional shearinine A-related metabolites (11, 12) (Figure 4) from the 
EtOAc extract of the fungus Penicillium janthinellum, which was collected from bottom sediments in 
Amursky Bay, Russia. 
 
Figure 4. Structure of shearinine A (10) and its derivatives (11–13). 
The new shearinine derivatives (11 and 12) were incorrectly named shearinine D and E [61], 
respectively, which were incorrect because these names had already been used by Xu et al. in their 
previous report [59] to describe other shearinine derivatives. Additionally, shearinine K (13) (Figure 4) 
was wrongly reported as a new compound called shearinine F by Smetanina et al.; it was incorrectly 
reported because it had already been isolated [59,61]. Although shearinine A (10) and its derivatives 
11 and 12 induced apoptosis in human leukemia HL-60 cells, compound 12 also inhibited the  
EGF-induced malignant transformation of JBC-P+-CI41 cells in a soft agar model [60]. 
The culture of the marine fungal strain Penicillium sp. F23-2, which was obtained from a deep 
ocean sediment sample, yielded two new meleagrin analogs, namely meleagrin D (14) and E (15) 
(Figure 5) [62], in addition to the previously reported meleagrin (16) and meleagrin B (17) (Figure 5) [63].  
Although the two new meleagrin analogs 14 and 15 displayed only modest cytotoxic activity against 
the A-549 cell line, meleagrin B (17) induced HL-60 cell apoptosis, and meleagrin (16) arrested the 
Shearinine A (10)
Shearinine K (13)
(11) (H22, H23-trans)
(12) (H22, H23-cis)
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cell cycle through the G2/M phase [62]. Meleagrin (16) was later reported from other marine-derived 
Penicillium spp., and it exhibited relevant cytotoxic activity against several cancer cell lines [64,65]. 
 
Figure 5. Structure of meleagrin (16) and meleagrin B (17), D (14) and E (15). 
Neoechinulin A (18) (Figure 6), a prenylated diketopiperazine alkaloid commonly reported from 
marine-derived Eurotium fungal strains [66–68], was isolated from the fungus Microsporum sp. MFS-YL, 
obtained from the surface of a red alga, which was collected at Guryongpo, PoHang in the Republic of 
Korea [69]. Neoechinulin A (18) displayed cytotoxic effects against human cervical carcinoma HeLa 
cells, and its induction of apoptosis in HeLa cells occurred through the down-regulation of Bcl-2 
expression, the up-regulation of Bax expression, and the activation of the caspase-3 pathway [69]. 
 
Figure 6. Structure of neoechinulin A (18) and fumigaclavine C (19). 
Meleagrin D (14) R =
Meleagrin E (15) R = 
Meleagrin (16) Meleagrin B (17)
 
Fumigaclavine C (19)
Neoechinulin A (18)
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A marine-derived strain of Aspergillus fumigatus, isolated from the surface of an unidentified alga, 
which was collected at Seosaeng-myeon in the Republic of Korea, was found to produce the indole 
alkaloid fumigaclavine C (19) (Figure 6) [70]. Fumigaclavine C (19) displayed pro-apoptotic effects in 
human MCF-7 breast cancer cells as well as the inhibition of MMP-2 and MMP-9 protease activity in 
these MCF-7 cells [70]. Fumigaclavine C (19) also down-regulated the NF-κB cell survival pathway [70]. 
The mangrove endophytic fungus Nigrospora sp. No. 1403, which was collected from the South 
China Sea, was found to produce three anthracenediones with interesting anticancer properties, namely 
bostrycin (20), SZ-685C (21) and 1403P-3 (22) (Figure 7) [71]. Bostrycin (20) and SZ-685C (21) are 
tautomers, and 1403P-3 (22) is a structural isomer, differing only in the position of the methoxyl 
substituent. Interestingly, bostrycin (20) was also reported in other marine-derived fungal species 
belonging to distinct genera such as Aspergillus, Fusarium and Xylaria [72–74]. 
 
Figure 7. Structure of bostrycin (20), SZ-685C (21) and 1403P-3 (22). 
Bostrycin (20) induces apoptosis in A549 non-small cell lung cancer (NSCLC) cells [75]. The 
bostrycin-induced pro-apoptotic effects in A549 NSCLC cells could be related to the up-regulation of 
microRNA-638 and microRNA-923 and the down-regulation of the PI3K/AKT protein pathway [75]. 
Bostrycin-induced cell death was promoted in the YCA1 null yeast strain but was partially rescued in 
the AIF1 null mutant in both fermentative and respiratory media, strongly indicating that bostrycin 
(20) induces apoptosis in yeast cells through a mitochondria-mediated but caspase-independent 
pathway [76]. A series of bostrycin derivatives was synthesized, and their cytotoxic activities were 
evaluated against MCF-7, MDA-MB-435, A549, HepG2 and HCT-116 cancer cells, with several 
compounds showing comparable cytotoxic activity to that of epirubicin [77]. However, these 
compounds also exhibited cytotoxicity towards normal MCF-10A breast cells [77].  
SZ-685C (21), a bostrycin tautomer, induces pro-apoptotic effects in various cancer cell lines 
through the Akt/FOXO pathway [78]. SZ-685C (21) exhibited a direct apoptosis-inducing effect 
through both the extrinsic and intrinsic apoptotic pathways, and the phosphorylation of Akt and its 
downstream effectors, which are forkhead box protein O1 and forkhead box protein O3a, were  
down-regulated in SZ-685C-treated cancer cells [78]. Furthermore, the pro-apoptotic protein Bim  
was up-regulated by SZ-685C treatment, which is consistent with FOXO dephosphorylation [78]. 
Wang et al. [79] have noted that radioresistance is a major obstacle to the treatment of human 
nasopharyngeal carcinoma (NPC), and emerging evidence has demonstrated that miRNAs are involved 
in cancer therapy resistance. The miR-205-PTEN-Akt pathway is the key cell signaling pathway, and 
it is activated in the CNE2R cells upon SZ-685C treatment [79]. However, the Stat3-Jab1-p27 pathway 
might participate in the pro-apoptotic effect on CNE2 cells but not on CNE2R cells [79]. SZ-685C 
Bostrycin (20) SZ-685C (21) 1403P-3 (22)
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(21) exhibited pro-apoptotic activity in both radiosensitive and radioresistant NPC cells [79]. 
Although the mechanisms for the two cell lines were not identical, the pro-apoptotic effects were 
similar in both cell lines [79]. Additionally, SZ-685C (21) suppressed the Akt pathway and induced 
apoptosis in MCF-7/adriamycin (ADR) and MCF-7/Akt breast cancer cells that are resistant to ADR 
treatment, leading to antitumor effects both in vitro and in vivo [80].  
Similarly, 1403P-3 (22) also induced apoptosis in human breast cancer cells by blocking Akt 
activation [81]. 1403P-3 (22) showed potent cytotoxicity not only in drug-sensitive human epidermoid 
carcinoma parental KB cells but also in MDR KBv200 cells [82]. The apoptosis-inducing effect of this 
compound on KB and MDR KBv200 cells is mediated through the mitochondrial and death receptor 
pathways, with the mitochondrial pathway being independent of ROS (reactive oxygen species) and 
the activation of caspase-8 [82]. 
Dimeric anthraquinones known as alterporriols K (23) and L (24) (Figure 8) were reported from the 
endophytic fungus Alternaria sp. ZJ9-6N, which was isolated from the fruit of the marine mangrove 
Aegiceras corniculatum in Zhanjiang, Guangdong province, China [83]. Both 23 and 24 displayed 
modest cytotoxic activity against two human breast cancer cell lines (MDA-MB-435 and MCF-7) [83]. 
Further studies were performed to elucidate the molecular mechanisms underlying the alterporriol L 
(24) cytotoxic effect, showing that induced apoptosis and necrosis. As suggested by the increased 
levels of cytosolic free calcium and ROS production as well as the induced loss of MMPo in 
alterporriol L-treated MCF-7 cells, the apoptotic and necrotic effects are supposedly derived from the 
destruction of mitochondrial functions [84].  
 
Figure 8. Structure of alterporriol K (23) and L (24). 
Aspergiolides A–D (25–28) (Figure 9) are cytotoxic anthraquinone derivatives with a  
naphtho[1,2,3-de]chromene-2,7-dione skeleton, and they were isolated from an EtOAc extract of 
cultures of the fungus Aspergillus glaucus HB1-19, which was obtained from a marine sediment 
collected in Fujian province, China [85–88]. 
Aspergiolide A (25) displayed an inhibitory activity against topoisomerase II that is comparable to 
that of adriamycin. This compound also induced apoptosis in hepatocellular carcinoma BEL-7402 cells 
via a caspase-dependent pathway [89]. Aspergiolides C (27) and D (28) were tested against a panel of 
14 tyrosine kinases, revealing selective inhibitory kinase activities that displayed potent inhibitory 
activity in c-Met and the modest inhibition of RON and c-Src [88]. The selective inhibition of c-Met is 
apparently derived from the novel spiro [5.5.] undecane scaffold that binds to a specific site of the  
 
Alterporriol L (24)Alterporriol K (23)
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c-Met catalytic domain [88]. Furthermore, both enantiomers (27 and 28) significantly inhibited  
HGF-promoted MDCK cell migration by targeting the HGF/c-Met pathway [88].  
Aspergiolide A (25) R = H
Aspergiolide B (26) R = Me
Aspergiolide C (27) R = H
Aspergiolide D (28) R = Me  
Figure 9. Structure of aspergiolide A (25), B (26), C (27) and D (28). 
In a recent study by Wijesekara et al. [90], the anthraquinone physcion (29) (Figure 10), which is 
also known as parietin, was isolated from a culture of the fungus Microsporum sp. MFS-YL which was 
obtained from the surface of the alga Lomentaria catenata collected at Guryongpo, PoHang, the 
Republic of Korea. Physcion (29) displayed pro-apoptotic effects in HeLa cells by down-regulating 
Bcl-2 expression, up-regulating Bax expression, activating the caspase-3 pathway and forming ROS [90]. 
 
Figure 10. Structure of physcion (29) and dicitrinone B (30). 
Dicitrinone B (30) (Figure 10), a member of a novel class of carbon-bridged citrinin dimers, was 
isolated from the marine-derived fungus Penicillium citrinum HGY1-5 from crater ash collected from 
the extinct volcano in Huguangyan, China [91]. This compound inhibited the proliferation of multiple 
tumor types, including the human A375 melanoma cell line [92]. In addition to inducing G2/M phase 
cycle arrest in the leukemia cell line HL-60 [91], dicitrinone B (30) is also a pro-apoptotic agent with 
effects that are triggered by ROS accumulation and MMPo reduction [92]. Dicitrinone B (30) activates 
both intrinsic and extrinsic apoptosis pathways under the regulation of Bcl-2 family proteins in the 
human A375 melanoma cell model [92]. 
Isosclerone (31) (Figure 11) is a naphthalenone that is commonly isolated from marine fungal 
sources [93–95], and it was recently reported in a strain of Aspergillus fumigatus obtained from a 
green alga that was collected at Seosaeng-myeon in the Republic of Korea [96]. Isosclerone-induced 
 
Dicitrinone B (30)Physcion (29)
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pro-apoptotic effects in human breast cancer MCF-7 cells resulted from the down-regulation of Bcl-2 
family protein expression, the up-regulation of caspases, and the activation of the NF-κB signaling 
pathway [97]. This compound also acts on MMP, inhibiting MMP-2 and -9 activities at both the 
protein and gene levels, and it had a dose-dependent inhibitory effect on the expression of MAPK 
proteins ERK, JNK and p38 MAPK [96]. Furthermore, this fungal metabolite inhibited cell cycle 
progression in MCF-7 cells through the down-regulation of CDK2, CDK4, cyclin B1 and cyclin E 
protein expression [96]. 
 
Figure 11. Structure of isosclerone (31) and cryptosphaerolide (32). 
Because of the relevant cytotoxic activity of the crude extract from fungal strain Cryptosphaeria sp. 
CNL-523, which was isolated from an unidentified ascidian collected in the Bahamas, Oh et al. [98] 
performed a chemical investigation leading to the identification of the sesquiterpenoid cryptosphaerolide 
(32) (Figure 11). In addition to its relevant cytotoxic activity against the HCT-116 human colon 
carcinoma cell line, cryptosphaerolide (32) was also identified as an inhibitor of Mcl-1 protein [98], 
which is a key player in apoptosis [99]. 
2.2. Metabolites That Kill Cancer Cells without Direct Pro-Apoptotic Effects 
Oxaline (33) (Figure 12), the 9-O-methyl analog of meleagrin (16) (Figure 5), was isolated from the 
culture of a marine sponge-associated Penicillium sp., and also from an unidentified algicolous  
fungus [100,101]. Analogous to some naturally derived chemotherapeutic agents such as colchicine, 
vinblastine and taxol, oxaline (33) causes cell cycle arrest in the M phase but not G2 phase arrest [102]. 
Oxaline (33) inhibits the in vitro polymerization of microtubule protein and purified tubulin in a  
dose-dependent manner. Furthermore, oxaline (33) was shown to inhibit the binding of [3H] colchicine 
to tubulin, but not that of [3H] vinblastine in a binding competition assay [102]. 
Protuboxepin A (34) (Figure 12) belongs to a rare class of naturally occurring diketopiperazine 
alkaloids containing an oxepin ring system, and it was originally isolated from the EtOAc extract from 
the culture of Aspergillus sp. SF-5044, which was isolated from a sediment sample collected from 
Dadaepo Beach, Busan, Korea [103]. Recently, protuboxepin A (34) was also reported as a product of 
Cryptosphaerolide (32)
Isosclerone (31)
Mar. Drugs 2015, 13 3962 
 
the co-fermentation of two algicolous fungi of the genus Aspergillus (BM-05 and BM-05L) [104]. In 
addition to its modest growth inhibitory effect against cancer cell lines [103], protuboxepin A (34) was 
further investigated to elucidate its cytotoxic mechanism. The preliminary results revealed increased 
subG1 and G2/M phase populations in protuboxepin A-treated Hep3B and MDA-MB-231 cells, in 
addition to the induction of Bcl-2 (Ser70), the decreased phosphorylation of cdc2 (Tyr15) and the 
induced cleavage of apoptotic markers in Hep3B cells, suggesting that the cytotoxic activity of 
protuboxepin A (34) was caused by tubulin inhibition [105]. Protuboxepin A’s (34) microtubule-stabilizing 
activity was further confirmed when this metabolite was associated with α/β-tubulin heterodimers, 
consequently leading to chromosome misalignment in the nuclei via accelerated tubulin 
polymerization [105]. Furthermore, when using an EB1-EGFP-expressing HeLa cell system, 
protuboxepin A (34) was found to cause a marked and rapid suppression of EB1-EGFP signals, 
confirming its inhibitory effect on microtubule dynamics [105]. Asami et al. [105] described 
protuboxepin A (34) as a microtubule-stabilizing agent, which has a distinct chemical structure from 
the previously reported microtubule inhibitors, such as taxanes and vinca alkaloids. 
 
Figure 12. Structure of oxaline (33) and protuboxepin A (34). 
Epoxyphomalins A–E (35–39) (Figure 13) belong to a small class of meroterpenoids, which are 
characterized by a sesquiterpene epoxycyclohexenone skeleton. They were produced by the fungus 
Paraconiothyrium cf. sporulosum, which was isolated from the marine sponge Ectyplasia perox that 
was collected at Lauro Club Reef, Dominica [106,107].  
Epoxyphomalins A (35) and B (36) exhibited potent in vitro growth inhibitory activity in 12 and 8 
of the 36 tested human tumor cell lines [106], respectively, and epoxyphomalin D (38) was particularly 
cytotoxic toward prostate PC3M and bladder BXF1218L cancer cell lines [107]. Apparently, the 
substituents at C-1 are involved in cytotoxic activity given that epoxyphomalins C (37) and E (39) 
(which have a large polar carboxylic acid functionality) displayed significantly lower cytotoxicity [107]. 
Because of the unique activity profile of the COMPARE analysis, the epoxyphomalin A mode of action 
(35) seemed to be distinct from those of reference anticancer agents [106]. Both epoxyphomalins A 
(35) and B (36) displayed potent inhibitions of the proteasome complex, exhibiting the inhibitory 
activity of chymotrypsin-, caspase-, and trypsin-like proteasomes in the purified human 20S 
proteasomes incubated with both compounds [107]. 
Protuboxepin A (34)Oxaline (33)
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Figure 13. Structures of epoxyphomalins A–E (35–39). 
Phomopsidin (40) (Figure 14) is a potent inhibitor of microtubule assembly, and it was isolated 
from an extract of Phomopsis sp. (strain TUF95F47) that was in turn isolated from a coral reef in 
Pohnpei [108,109]. Phomopsidin (40) inhibits microtubule assembly with an IC50 of ~6 μM, which is 
similar in potency to that of colchicine (IC50 = 10 μM) and rhizoxin (IC50 = 4 μM) [108,109]. A further 
antimitotic activity screening of compounds that are structurally similar to phomopsidin (40) indicates 
that the cis-decaline structure may play a key role in their antimicrotubule activity [109,110].  
 
Figure 14. Structure of phomopsidin (40), MK8383 (41) and phomopsidin methylester derivative (42). 
The (16Z)-isomer of phomopsidin (40), which is called MK8383 (41) (Figure 14), also displayed 
potent antimicrotubule activity (IC50 = 8 μM), suggesting that the geometry at Δ16,17 did not affect the 
bioactivity, and the lack of activity of the phomopsidin methylester derivative (42) (Figure 14) and 
several structurally related compounds revealed that the free carboxylic acid moiety is essential for the 
inhibitory activity against microtubule assembly [111,112]. 
Ascosalipyrrolidinone A (43) (Figure 15) is another marine fungal-derived tyrosine kinase inhibitor 
with an unusual tetramic acid skeleton. It was isolated from the EtOAc extract of a culture of the 
obligate endophytic fungus Ascochyta salicorniae that was obtained from a green alga Ulva sp. 
collected off the North Sea by Tӧnning in Germany [113]. This compound caused 70% activity 
inhibition of p56lck at the concentration of 40 μg/mL [113]. 
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Figure 15. Structure of ascosalipyrrolidinone A (43). 
Three hydrogenated azaphilones called pinophilins A (44) and B (45) and Sch 725680 (46) 
(Figure 16) were isolated from cultures of the fungus Penicillium pinophilum Hedgcok. This fungus 
was derived from seaweed collected along the coast of Kasai Marine Park in Tokyo, Japan [114]. 
These fungal metabolites displayed inhibitory activities against mammalian DNA polymerases (pols) 
A (pol γ), B (pols α, δ, and ε), and Y (pols η, ι, and κ) families, but they had no inhibitory activity 
against the four X-family pols (pols β, λ, μ, and terminal deoxynucleotidyl transferase) [114]. 
Additionally, no activity or only a minimal influence was detected on the activities of plant and 
prokaryotic pols or any other DNA metabolic enzymes, indicating specific inhibitory activities for A-, 
B-, and Y-family pols. Pinophilin A (44) displayed the strongest inhibitory activity on the DNA pols, 
and it exhibited a noncompetitive inhibitory activity against both pols α and κ with the DNA  
template-primer substrate, and competitive inhibitory activity with the nucleoside substrate [114]. 
Furthermore, pinophilins A (44) and B (45) and Sch 725680 (46) suppressed cell proliferation and 
growth in five human cancer cell lines, leading to cell cycle arrest at the S phase in BALL-1 and 
HCT116 cells, with no cytotoxicity against normal human cell lines [114]. The correlation between the 
inhibitory effects of cancer cell growth and the inhibition of B-family pols, which are essential for 
DNA replication during cell proliferation, indicate that the anticancer activity of these compounds was 
caused by the inhibition of DNA replication [114]. 
 
Figure 16. Structure of pinophilin A (44), pinophilin B (45) and Sch 725680 (46). 
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A chemical investigation of the EtOAc extract of a culture of the algicolous fungus Wardomyces 
anomalus, which was collected around Fehmarn Island in the Baltic Sea, resulted in the  
isolation of several xanthones, including anomalin A (47) and norlichexanthone (48), as well as  
5-(hydroxymethyl)-2-furanocarboxylic acid (49) (Figure 17) [115]. All these compounds caused 100% 
inhibition of p56lck tyrosine kinase at 200 μg/mL [115].  
 
Figure 17. Structure of anomalin A (47), norlichexanthone (48) and 5-(hydroxymethyl)-2-
furanocarboxylic acid (49). 
Anomalin A (47) and norlichexanthone (48) were later reported in the cytotoxic extract of the 
fungus Arthrinium sp., which was isolated from the marine sponge Geodia cydonium that was 
collected from the Adriatic Sea [116]. In addition to their strong cytotoxic activity against a panel of 
human and murine cell lines, anomalin A (47) and norlichexanthone (48) also exhibited inhibitory 
activity against several cancer-related protein kinases. Anomalin A (47) and norlichexanthone (48) 
markedly inhibited the activity of the protein kinases aurora-B, PIM1 and VEGF-R2 with mean IC50 
values ranging from 0.3 to 0.8 μM and 0.3 to 12 μM, respectively [116].  
Chaetominedione (50) (Figure 18) is a benzonaphthyridinedione derivative, and it was isolated from 
an extract of the fungus Chaetomium sp., which was obtained from Valonia utricularis alga that was 
collected from Azores, Portugal [117]. This compound has significant inhibitory activity toward p56lck 
tyrosine kinase (94% enzyme inhibition at 200 μg/mL) [117], which is the enzyme that is involved in 
tumor cell biology under hypoxic environments [118]. 
 
Figure 18. Structure of chaetominedione (50) and pulchellalactam (51). 
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Pulchellalactam (51) (Figure 18) was isolated from the EtOAc extract of a culture of the driftwood 
marine fungus Corollospora pulchella ATCC 62554, which was collected from Peleliu, Palau [119]. 
Pulchellalactam (51) exhibited dose-dependent inhibitory activity against the CD45 protein tyrosine 
phosphatase, which plays central signaling roles in dephosphorylating Src-kinases, and this compound 
therefore represents an attractive drug target [119]. 
A bioassay-guided fractionation of the EtOAc extract from a culture of the fungus Microsporum cf. 
gypseum isolated from a bryozoan Bugula sp. that was collected in the Virgin Islands yielded two 
cyclic tetrapeptides known as microsporins A (52) and B (53) (Figure 19) [120]. Both peptides 
displayed strong cytotoxic activity against human colon adenocarcinoma HCT-116 cells; however, 
microsporin B (53) showed reduced activity (IC50 = ~9 μg/mL) compared with microsporin A (52) 
(IC50 value of 0.6 μg/mL), suggesting that the carbonyl group of the oxodecanoic acid moiety may 
influence the cytotoxicity [120]. 
Microsporin B (53)Microsporin A (52)  
Figure 19. Structure of microsporin A (52) and B (53). 
Microsporin A (52) also exhibited significant cytotoxicity against an NCI 60 cancer cell panel with 
a mean IC50 of ~3 μM [120]. This compound displayed potent in vitro inhibitory activity against a 
mixture of HDACs and HDAC8, exhibiting stronger activity than the anticancer HDAC agent 
vorinostat [120]. 
A chemical investigation of the fungus Tolypocladium sp. AMB18, which was isolated from sea 
mud collected in Aomori prefecture, Japan, resulted in the isolation of thee linear pentadecapeptides 
called efrapeptins F (54), G (55) and J (56) [121] (Figure 20). 
These peptides inhibited the luciferase expression caused by 2-deoxyglucose in HT1080 human 
fibrosarcoma cells, with IC50 values of ~9, ~3 and 18 nM, respectively. Efrapeptin J (56) also acts as a 
down-regulator of the molecular chaperone GRP78 in HT1080 and MKN74 human gastric cancer 
cells, and it induced cell death in HT1080 cells under endoplasmic reticulum stress [121]. Molecular 
chaperone GRP78 is an important target for the development of anticancer agents because of its key 
roles in cancer cell biology, namely in chemoresistance [122,123]. 
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Figure 20. Structure of efrapeptin F (54), G (55) and J (56). 
 
Figure 21. Structure of pericosine A (57), B (58) and D (59). 
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2.3. Metabolites with in Vivo Antitumor Activity or Those Entering Clinical Trials 
Pericosines A (57), B (58) and D (59) (Figure 21) are cytotoxic metabolites that belong to a small 
class of cyclohexenoids produced by the fungal strain Periconia byssoides OUPS-N133 which was 
isolated from the gastrointestinal tract of the sea hare Aplysia kurodai [124,125]. The three fungal 
metabolites exhibited pronounced in vitro cytotoxic activity against murine P388 cells, and pericosine 
A (57) also displayed selective and potent cytotoxicity against HBC-5 and SNB-75 human cancer cell 
lines [125]. Interestingly, when compared with natural pericosine B (58), its synthetic C-6 epimer 
displayed significantly weaker cytotoxicity against the murine P388 cell line, suggesting that the 
stereochemistry of C-6 may have a preponderant role in pericosine B (58) activity [126]. 
In addition to its inhibitory activity against protein kinase EGFR and human topoisomerase II [125], 
pericosine A (57) displayed significant in vivo inhibitory activity in mice that were inoculated 
intraperitoneally (i.p.) with P388 leukemia cells, leading to increased survival days in mice administered 
i.p. with 25 mg/kg of the metabolite [124,125]. It should nevertheless be emphasized that although 
murine cancer models are useful for studying the in vivo anticancer effects of various types of compounds, 
they are actually not representative of the biology of human cancers in a clinical setting [127]. 
Spiroxin A (60) (Figure 22), which is a cytotoxic antibiotic, was produced by an unidentified fungus 
(strain LH-37H248) isolated from a soft coral that was collected from Dixon Bay, Canada [128]. 
Spiroxin A (60) displayed potent cytoxicity (IC50 = 0.09 μg/mL) against a panel of 25 diverse cell 
lines, which were supposedly partially derived from single-stranded DNA cleavage [128]. Spiroxin A 
(60) contains an unusual bisnaphthospiroketal octacyclic ring system with the spiroketal carbon 
oxidation state, allowing it to behave chemically as a quinone epoxide and leading to DNA cleavage 
via an oxidative stress mechanism involving thiol conjugates [128]. 
Spiroxin A (60)  
Figure 22. Structure of spiroxin A (60). 
Spiroxin A (60) also displayed in vivo antitumor activity in nude mice against ovarian carcinoma, 
causing 59% inhibition after 21 days at a 1 mg/kg dose administered i.p. on days 1, 5, and 9  
post-staging [128]. The fact that ovarian cancers do not develop subcutaneously in clinical  
situations [129] makes it difficult to assess the actual value of this in vivo assay because there was no 
indication as to whether the ovarian cancer was grafted subcutaneously (s.c.) or orthotopically. 
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Breast cancer remains one of the most common cancers, and anthracyclines, including adriamycin, 
are commonly used as breast cancer chemotherapeutic drugs [130–132]. The HER2/PI3K/Akt 
signaling pathway is one of the multidrug-related pathways, and it is involved in breast cancer 
chemoresistance against a panel of anticancer drugs such as the anthracyclines adriamycin, epirubicin 
and mitoxantrone [133]. The previously mentioned pro-apoptotic SZ-685C (21) (Figure 23), which 
displayed inhibitory activity against the proliferation of six human breast cancer cell lines [78], also 
markedly inhibited tumor growth in nude mice that were inoculated s.c. in the right mammary gland 
with human breast MDA-MB-435 cancer cells. With an i.p. dose of 50 mg/kg body weight, this 
compound led to 61% inhibition in the xenografted tumor growth after 35 days, with no detectable 
toxicity [78]. SZ-685C (21) also caused a significant inhibition in the growth of MCF-7/ADR 
xenografted tumors in nude mice. In contrast to the reference breast chemotherapeutic agent 
adriamycin, which causes a certain degree of toxicity as well as significantly lower inhibitory activity 
(28%) [80], the i.p. administration of SZ-685C (21) at 50 mg/kg body weight caused 64% inhibition in 
tumor growth with no detectable toxic effects. 
 
Figure 23. Structure of SZ-685C (21) and ophiobolin O (61). 
Ophiobolin O (61) (Figure 23), which is a sesterterpene with an unusual tetracyclic ring system that 
was isolated from Aspergillus ustus 094102, was reported as pro-apoptotic in human MCF-7 breast 
cancer cells [134]. Ophiobolin O (61) causes the activation of JNK, p38 MAPK and ERK, as well as 
the degradation of Bcl-2 phosphorylation (Ser70) [134]. Ophiobolin O (61) also decreases the 
phosphorylation level of AKT and GSK3β, as well as the induction of cyclin D1 down-regulation [135]. 
Furthermore, this compound was found to reverse MCF-7/ADR resistance to adriamycin [136], and its 
reversal effect may be related to the reduction in resistance-related protein P-glycoprotein (P-gp, also 
known as MDR1) by inhibiting the activity of the multidrug resistance 1 (MDR1) gene promoter, 
which makes MCF-7/ADR cells more sensitive to adriamycin treatment [136]. Ophiobolin O was also 
found to suppress tumorigenesis in the xenograft mouse model that was injected s.c. with MCF-7 cells. 
The intravenous (i.v.) administration of 5, 10 and 20 mg/kg of ophiobolin O (61) led to 35%, 46% and 
69% tumor growth inhibitory rates, respectively, after 50 days of treatment, displaying almost no 
toxicity [136]. At a dose of 20 mg/kg, the compound showed nearly equivalent inhibitory activity to 
the activity in a paclitaxel-treated mouse, which caused 73% tumor growth inhibition [135]. Although 
the i.v. administration of 5 mg/kg ophiobolin O (61) and adriamycin alone produced MFC-7/ADR 
tumor growth inhibitory rates of 23% and 46% in a nude mice xenograft model, respectively, the 
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combined treatment (5 mg/kg) revealed a strong reversal effect leading to an inhibition rate of  
71% [136]. The improved antitumor effect of adriamycin, in combination with ophiobolin O (61), 
confirmed its potential as a lead candidate to reverse chemotherapy drug resistance in breast  
cancer [136].  
Secalonic acid D (62) (Figure 24) is a toxic and teratogenic dimeric xanthone that has been widely 
reported in marine-derived fungal strains [137–141]. It exhibited an inhibitory effect on the K562 
leukemia cell line, causing a concentration-dependent block in the G0/G1 cell cycle phase [137,138,142] 
as well as apoptosis induction and cell cycle arrest in the G1 phase in K562 and HL60 cells [143]. 
Although the apoptotic effect apparently derives from the cleavage of caspase-3 and PARP, the cell 
cycle arrest in the G1 phase seems to be related to the down-regulation of the proto-oncogene c-Myc [138]. 
The decreased expression of c-Myc and the subsequent down-regulation of cyclin D1, CDK4 and 
E2F1 by secalonic acid D (62) apparently derive from the activation of p-GSK-3α/β following the 
breakdown of β-catenin [138]. In addition to its potent cytotoxic effect on MDR and parental cells, 
secalonic acid D (62) also exhibited remarkable cytotoxicity against lung cancer cells A549, GLC82 
and H460, with IC50 values of 0.3, 0.3 and 0.1 μM, respectively [143]. Secalonic acid D (62) was also 
evaluated for its activity against the overexpression of ABCG2 protein, which is the major mechanism 
responsible for chemotherapy resistance in S1-M1-80 cells [144], and it was found to quicken the 
degradation of ABCG2 through the activation of calpain 1 in S1-M1-80 cells. This effect is supposedly 
related to the decreased percentage of side population cells, which are resistant to chemotherapeutic 
agents such as doxorubicin and cisplatin [143]. Secalonic acid D (62) was also identified as a 
topoisomerase I inhibitor. Unlike camptothecin, the lead metabolite of the anticancer drugs irinotecan 
and topotecan, secalonic acid D (62) was found to hamper the formation of topoisomerase I-DNA 
covalent complexes [145]. A further evaluation of the secalonic acid D (62) topoisomerase I inhibition 
mechanism by docking studies revealed its strong binding activity with the catalytic residues ARG488 
and LYS532, as well as with ARG590 and TYR723 through its two carbonyl groups and hydroxyl 
moieties [141]. These results indicated that secalonic acid D (62) inhibited DNA molecules from 
binding with the catalytic residues or even the catalytic region [141]. The in vivo antitumor activity of 
secalonic acid D (62) in mouse hepatoma H22-inoculated mice xenografts was also evaluated [141]. 
This compound was found to inhibit tumor cell growth at an inhibitory rate that was significantly higher 
than that of 5-fluorouracil (5-FU) (42% versus 38%) at 15 and 20 mg/kg, respectively. Furthermore, 
when compared with 5-FU, the weight of secalonic acid D-treated mice did not change significantly, 
indicating the lower toxicity of secalonic acid D (62) [141]. The in vitro and in vivo antitumor effect of 
the 5,5′-bis(2′-tetrahydropyranyl) derivative of secalonic acid D (63) was also assayed [146]. The 
synthetic derivative (63) (Figure 24) exhibited in vitro inhibitory activity similar to that of mitomycin 
C against syngeneic fibrosarcoma Meth-A cells. This compound also showed in vivo antitumor activity 
against BALB/c mice bearing Meth-A cells, supposedly through direct interactions with the Meth-A 
cells [146].  
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Figure 24. Structure of secalonic acid D (62) and its synthetic derivative (63). 
Aspergiolide A (25) (Figure 25) also displayed significant in vivo antitumor activity in both H22 
and BEL-7402 hepatocellular carcinoma xenografts [89]. The i.p. administration of aspergiolide (25) 
significantly inhibited the growth of H22 subcutaneous cancer with a higher inhibitory rate and lower 
toxicity than that of adriamycin. I.p. administration of aspergiolide A (25) resulted in relevant 
anticancer activity in BEL-7402 xenografts; however, the inhibitory rate and impact of aspergiolide A 
(25) on mouse body weight reduction were lower than the reductions in ADR-treated mice [89]. 
 
Figure 25. Structure of aspergiolide A (25). 
An early safety evaluation of aspergiolide A (25) revealed maximum tolerable doses in mice that 
were superior to 400 mg/kg, exceeding the effective dose 10 times. Because no significant increase in 
micronucleus rates or inhibitions of the hERG channel was observed, the compound was not 
considered to be genotoxic or cardiotoxic [89]. Furthermore, an evaluation of pharmacokinetic parameters 
and tissue distribution indicated that aspergiolide A (25) could be rapidly cleared in vivo in a first-order 
reaction kinetic manner, and the compound was enriched in cancer tissue [89]. Moreover, the 
compound was taken up well by Caco-2 cells and absorbed through the active transport pathway [89]. 
5,5'-bis(2'-tetrahydropyranyl) secalonic acid D (63)
Secalonic acid D (62)
Aspergiolide A (25)
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An extract of the endophytic fungus Aspergillus wentii EN-48 that was isolated from marine alga 
Sargassum sp. displayed relevant cytotoxic activity against several human tumor cell lines, leading to 
the chemical investigation of its bioactive metabolites [147]. The fungus was found to produce 
asperolide A (64) (Figure 26) in addition to the structurally related norditerpene dilactones called 
wentilactones A (65) and B (66) (Figure 26) [147]. Despite their modest cytotoxic activity against a 
panel of human tumor cell lines, these compounds inhibited the proliferation of human cancer cells by 
G2/M arrest as well as by inducing apoptosis [148,149]. Asperolide A (64) exerted an antiproliferative 
effect on human NCI-H460 lung carcinoma cells through the activation of the Ras/Raf/MEK/ERK 
signaling and p53-dependent p21 pathways [148]. Similarly, wentilactone A (65) directly targeted 
HRas-GTP, excessively activating the Ras/Raf/ERK pathway and inducing apoptosis and cell cycle 
arrest in both NCI-H460 and NCI-H446 lung cancer cell lines [149]. The apoptotic effect of 
wentilactone A (65) is also apparently mediated by ROS accumulation [149]. Wentilactone B (66) also 
markedly induced cell cycle arrest at the G2 phase and mitochondrial-related apoptosis, accompanying 
the accumulation of ROS [150]. A pre-treatment of human hepatoma SMMC-7721 cells with 
wentilactone B (66) revealed a specific binding affinity toward Ras-GTP, suggesting that the 
compound causes cell cycle arrest in the G2 phase through the Ras/Raf/ERK signaling pathway, and it 
induces apoptosis via the Ras/Raf/JNK pathway [150]. Furthermore, wentilactone B (66) not only 
displayed a selective cytotoxic effect on SMMC-7721 cells, but also inhibited the metastasis of 
SMMC-7721 cells through the down-regulation of cell surface proteins CD44 and EGFR [151].  
 
Figure 26. Structure of asperolide A (64), wentilactone A (65) and B (66). 
In addition to their cytotoxic activity against a wide panel of cancer cell lines, asperolide A (64), 
wentilactone A (65) and wentilactone B (66) were able to suppress the in vivo tumor growth of  
in-mouse xenografted models [148–150]. The treatment of nude mice inoculated with NCI-H460 lung 
cancer cells with asperolide A (64) i.v. at 2.5 mg/kg promoted both tumor mass and volume reduction, 
causing a 68% inhibition of tumor growth. Unlike cisplatin-treated mice, which showed an inhibition 
ratio that was 14 times higher, asperolide A (64) led to weight gain, showing little toxicity compared 
with cisplatin [148]. Similar to asperolide A (64), wentilactone A (65) also displayed relevant in vivo 
inhibitory activity against NCI-H460 and NCI-H466-xenografted mice. In vivo wentilactone A (65) 
treatment caused an effective inhibitory effect in both xenografts with inhibition rates of 96% and 87%, 
respectively, showing effects equivalent to that of cisplatin i.v. at 2.5 mg/kg, but promoting weight 
Asperolide A (64) Wentilactone A (65) Wentilactone B (66)
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gain over the course of the therapy [149]. Consistent with the in vitro anticancer mechanism, a tumor 
immunohistochemical analysis revealed a relevant increase in active caspase-3 and the inhibition of 
cdc2 expression in wentilactone A-treated mice, in addition to increased levels of p-ERK and  
HRas-GTP, indicating the same cell signaling mechanism [149]. An in vivo antitumor activity 
evaluation revealed that the i.p. administration of wentilactone B (66) inhibited the growth of 
transplanted human hepatoma SMMC-7721 cells in a dose-dependent manner, leading to an 86% 
inhibition of tumor growth at a dose of 20 mg/kg [150]. Despite its significantly higher in vivo 
antitumor activity, 5-FU treatment caused a large body weight decrease in contrast to wentilactone  
B-treated animals, thus evidencing the lower toxicity of wentilactone B (66) [150]. A further analysis 
of wentilactone B-treated xenograft tissues revealed the up-regulation of Ras-GTP as well as the 
activation of ERK and JNK, confirming the involvement of the MAPK pathway in the wentilactone B 
(66) anticancer effect [150].  
Hirsutanol A (67) (Figure 27), a hirsutane-based sesquiterpene, was first reported in the salt water 
culture of an unidentified marine sponge-associated fungus (95-1005C) [152]. Hirsutanol A (67), as 
well as other derivatives of this class of sesquiterpenes, was later isolated from the EtOAc extract of a 
culture of the fungus Chondrostereum sp. SF002, which was isolated from the soft coral Sarcophyton 
tortuosum that was collected from Sanya Bay in the southern China Sea [153,154]. Hirsutanol A (67) 
was found to inhibit cell proliferation, elevate the ROS level, and induce apoptosis and autophagy in 
MCF-7 human breast cancer cells [155]. It therefore seems that hirsutanol A (67) could induce 
apoptosis and autophagy via the accumulation of ROS, and co-treatment with an autophagy inhibitor 
was able to sensitize MCF-7 cells to hirsutanol A (67) [155]. Hirsutanol A (67) also activates the JNK 
signaling pathway by elevating the ROS level [156]. In contrast with other hirsutane sesquiterpenoids, 
which lack the α-methylidene oxo group, hirsutanol A (67) displayed a potent cytotoxicity against 15 
distinct human cancer cell lines [153]. These results indicated that the α-methylidene oxo group is 
required for the cytotoxic activity of this class of sesquiterpenoids, possibly by enzymatic inactivation 
via alkylation [153]. 
 
Figure 27. Structure of hirsutanol A (67). 
Hirsutanol A (67) also exhibited an in vivo anti-tumor effect in a SW620 xenograft model, causing 
more than 50% inhibition in tumor growth at 10 mg/kg/day when administered i.p. [156].  
Plinabulin (NPI-2358) (68) (Figure 28), a selective tumor vascular disrupting agent, is the only 
marine-derived fungal metabolite-based compound that has entered clinical trials to date. Plinabulin 
(NPI-2358) (68) is a synthetic tert-butyl analog that is closely related to the naturally occurring fungal 
metabolite halimide (69) (Figure 28), also known as phenylahistin [157,158]. Halimide (69) was 
Hirsutanol A (67)
O
OH
O H
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isolated from cultures of the strain Aspergillus sp. CNC139, which was collected off the Philippine 
Islands [157,158], and almost simultaneously from two terrestrial strains of Aspergillus ustus [159].  
 
Figure 28. Structure of plinabulin (68) and halimide (69). 
In a panel of 38 human tumor cell lines, halimide (69) exhibited an in vitro growth inhibition profile 
that was similar to that of the vinca alkaloids or paclitaxel, suggesting that its target of action could be 
the microtubule system [159]. This finding was later confirmed by its inhibitory activity on the cell 
cycle progression of P388 cells in the G2/M phase [160] and the disruption of the microtubule network 
in A549 cells through interactions with the colchicine-binding site on tubulin [161]. Its promising  
in vivo antitumor activity against P388 leukemia cells and solid tumors of Lewis lung carcinoma [162] 
motivated the synthesis of several halimide analogs, and a cytotoxic activity evaluation led to the 
development of plinabulin (NPI-2358) (68) [163,164]. Plinabulin (68) displayed a potent in vitro 
antitumor activity against several human tumor cell lines including MDR cell lines [165], and similar 
to halimide (69), plinabulin was also identified as a potent microtubule-disrupting agent with 
colchicine-like tubulin-depolymerizing activity [166]. Additionally, plinabulin (68) induced monolayer 
permeability in normal human umbilical vein endothelial cells (HUVECs), displaying significantly 
more potent vascular disrupting activity than the tubulin-depolymerizing agents colchicine and 
vincristine [165]. Plinabulin (68) displays microtubule-disrupting and vascular disrupting activities, in 
addition to the tumor growth inhibitory activity of other preclinical models, and together with an 
ADMET parameter evaluation, it was classified as a clinical candidate [167]. A phase I first-in-human 
trial sponsored by Nereus Pharmaceuticals Inc. was performed to examine its safety, pharmacokinetics 
and pharmacodynamics as a single agent in patients with refractory solid tumors or lymphoma [168,169]. 
Phase I/II clinical trials of plinabulin (68) in combination with docetaxel was completed in 2011 in 
patients with advanced non-small cell lung cancer [170–172]. 
3. Which Compounds Are the Most Promising Marine-Derived Fungal Metabolites for Use as 
Potential Anticancer Agents? 
Gliotoxin (7), 5a,6-didehydrogliotoxin (8) and gliotoxin G (9) exhibit potent inhibitory activity 
against the methylation regulation enzymes HMT G9a and HMT Set7/9 [53], which are commonly 
involved in the malignant transformation of cells [58]. Kondo et al. [173] report that the knockdown of 
HMT G9a in human PC3 prostate cancer cells markedly inhibited cell growth and caused profound 
morphological changes with a loss of telomerase activity and shortened telomeres. Kondo et al. [173] 
 
Plinabulin (NPI-2358) (68) Halimide (Phenylahistin) (69)
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also reported that HMT G9a is required to perpetuate the malignant phenotype. These authors [173] 
accordingly claim that targeting HMT G9a may be of therapeutic benefit for cancers. Lee et al. [174] 
showed that hypoxia results in the up-regulation of HMT G9a, and the overexpression of HMT G9a 
attenuates RUNX3 expression, along with the fact that RUNX3 is a tumor suppressor [174]. These 
authors [174] thus argue that hypoxia silences RUNX3 by epigenetic histone regulation during the 
progression of gastric cancer. HMT G9a is also overexpressed in pancreatic adenocarcinoma, in which 
it promotes tumor invasiveness and metastasis [175]. BRD4770, which is a small-molecule inhibitor of 
HMT G9a, induces senescence in PANC-1 pancreatic cancer cells [175]. Adachi et al. [176] suggest 
that T-cadherin might inhibit tumor progression through multiple pathways including the HMT  
Set7/9-p53 pathway. It therefore seems to us that gliotoxin and some of its metabolites are actually 
potential anticancer drugs due to their anti-HMT G9a and Set7/9 activities, which represents an 
innovative mechanism of anti-cancer action.  
Bostrycin (20) and its analogs represent an interesting family of anticancer compounds for several 
reasons. Bostrycin induces apoptosis in A549 non-small cell lung cancer (NSCLC), and A549 cancer 
cells display certain levels of resistance to pro-apoptotic stimuli [177]. In the same manner, SZ-685C 
(21), a tautomer of bostrycin (20), is active against radioresistant nasopharyngeal cancer cells [79] and 
adriamycin-resistant breast cancer cells [80], and 1403P-3 (22), a bostrycin derivative (22), is also 
cytotoxic against MDR cancer cells [82]. In addition, although bostrycin (20) and its derivatives do not 
seem to be selective in vitro [77], SZ-685C (21) displays significant in vivo antitumor activity against 
adriamycin-resistant human breast xenografts with no detectable toxicity at effective doses in terms of 
anticancer activity [78,80]. All these features thus strongly suggest that bostrycin and its derivatives 
could be used as scaffolds to generate innovative anticancer agents. 
Pinophilin A (44) is a selective compound, i.e., it is cytotoxic against cancer but not against normal 
cells [114]. In addition to its selectivity between normal and cancer cells, pinophilin A (44) also 
displays a rather original mechanism of action through its inhibitory effects against specific 
mammalian DNA polymerases. This compound could therefore lead to innovative anticancer agents. 
Ophiobolin O (61) displays several mechanisms of action when killing cancer cells, including for 
example the inhibition of the activity of several kinases [134–136]. It is interesting to note that 
ophiobolin O (61) induces apoptosis in human MCF-7 breast cancer cells [134], and MCF-7 breast 
cancer cells are deficient in caspase-3 (a key player in apoptosis) activity [178]. A close analog of 
ophiobolin O, i.e., ophiobolin A, kills glioblastoma cells that are apoptosis-resistant [179] through 
paraptosis-related events [180]. Ophiobolin O (61) also reverses the resistance of human breast  
cancer cells to adriamycin [136], and it displays in vivo antitumor activity in human MCF-7 breast 
xenografts [136]. All these data strongly suggest that some ophiobolin derivatives could be used to 
combat various types of cancers that display various levels of resistance to pro-apoptotic stimuli.  
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4. How Could We Increase the Rate of Discovery of Marine-Derived Fungal Metabolites as 
Potential Anticancer Agents, at Least in Vitro? 
4.1. Are Pro-Apoptotic Compounds Still Valuable Weapons for Combating Cancer? 
Several cytotoxic marine-derived fungal metabolites that exhibit pro-apoptotic effects against 
cancer cells induce apoptosis through the inhibition of the Akt pathway as evidenced, for example, by 
leptosin C (3) [49], SZ-685C (21) [78] and ophiobolin O (61) [135]. The problem is that hundreds of 
articles have already described the use of Akt inhibitors to combat various types of cancers, and 
several Akt inhibitors are already in clinical trials [181–184]. It thus seems unlikely that compounds 
for which some in vitro data exist today with respect to their Akt inhibition activity would move 
toward clinical trials in the coming years with respect to this more-than-competitive area of Akt inhibitors.  
Another problem relating to the determination of the potential anticancer activity of marine-derived 
fungal metabolites is as follows. Many studies that emphasize the potential activity of marine-derived 
fungal metabolites are often obtained by using only one or two cancer cell lines, which are 
unfortunately sensitive-to-highly sensitive to pro-apoptotic stimuli. This is the case, for example, for 
fumigaclavine (19) [70], isosclerone (31) [96], ophiobolin O (61) [134] and hirsutanol A (67) [155], 
the anticancer activities of which were primarily characterized in the human MCF-7 breast cancer cell 
line, which is more or less sensitive to pro-apoptotic stimuli [178]. As by March 2015, the Scopus 
database includes more than 6400 publications for the keywords “MCF-7 AND apoptosis.” The  
HL-60 leukemia cell line is also used to characterize the mechanisms of action of marine-derived 
fungal metabolites for shearinine A (10), (11) and (12) [60,61], as well as for meleagrin D (14) and  
E (15) [62]. The Scopus database includes more than 5300 publications for the keywords “HL-60 AND 
apoptosis,” as of March 2015. Finally, the HeLa cervix carcinoma cell line is also used to characterize 
the potential anticancer activity of marine-derived fungal metabolites for gliotoxin (7) [55], neoechinulin 
A (18) [69], and physcion (29) [90]. The Scopus database includes more than 9700 publications for the 
keywords “HeLa AND apoptosis,” as of March 2015. Thus, the data that were obtained for cancer cell 
lines that are sensitive to highly sensitive to pro-apoptotic stimuli are at odds with respect to the 
clinical situation. In fact, cancers from patients with dismal prognoses are actually resistant to pro-apoptotic 
stimuli [179,185–191]. Thus, MCF-7, HeLa and/or HL60 cells cannot be used as predictive models 
with respect to cancer patients, and the fact that a given compound induces apoptosis in these MCF-7, 
HeLa and/or HL60 cells definitively does not mean that it is a promising anticancer agent. 
Pro-apoptotic agents that can be classified as promising anticancer agents must display pro-apoptotic 
effects against cancer cells that usually resist pro-apoptotic insults. Compounds that kill MDR and 
apoptosis-resistant cancer cells through non-apoptotic pathways should be privileged [42].  
4.2. Pharmacological and Toxicological Strategies 
When assayed in vitro, a compound that kills cancer cells is not a potential anticancer agent; it is 
just a poisonous compound. To become a potential anticancer agent, a cytotoxic compound must kill 
more cancer cells than normal cells. Thus, once a compound displays in vitro cytotoxic activity against 
cancer cells, it must be tested as soon as possible on normal cells to determine its level of selectivity 
between normal and cancer cells. Thus, if a compound of interest displays the same levels of toxicity 
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in normal and cancer cells, it cannot be labeled as a potential anticancer agent. It is just a non-selective 
poisonous agent [42]. 
If a compound that is assayed in vitro displays cytotoxicity against various cancer cell lines while 
still being selective towards normal cells, e.g., it is significantly less toxic against normal than cancer 
cells, this selective cytotoxic compound must then be assayed against several MDR cancer cell lines. 
In fact, many cytotoxic compounds that are assayed on chemoresistant cancer cells are rejected by 
these cancer cells thanks to various efflux pumps that form the so-called multidrug-resistant  
phenotype [42]. Large numbers of cytotoxic compounds are already routinely used to combat 
chemosensitive cancers. However, when these chemosensitive cancers are chronically treated with 
cytotoxic and/or pro-apoptotic drugs, they develop chemoresistance, given that the MDR phenotype is 
very efficient at inhibiting the cytotoxic activity of a large set of compounds of interest [42]. Thus, a 
selective (normal/cancer cells) cytotoxic compound must be assayed in MDR cancer cell lines in 
addition to conventional cancer cell lines. If the compound of interest is not active against MDR 
cancer cells and is cytotoxic against conventional cancer cell lines, it cannot be considered as a 
potential anticancer agent, even though it is selective between normal and cancer cells. For example, 
some marine-derived fungal metabolites with pro-apoptotic activity are active against MDR cancer 
cells. These compounds include, for example, bostrycin (20), SZ-685C (21) and 1403P-3 (22) [80,82]. 
However, it is not possible to know if these compounds are actually potential anticancer agents or 
simply highly poisonous compounds. Bostrycin derivatives also display cytotoxic activity against 
normal cells [77]. The cytotoxic effects of pro-apoptotic compounds against MDR cancer cells must 
therefore also be assayed in normal cells. Finally, compounds that induce cytotoxicity in highly 
apoptosis-sensitive cancer cells through pro-apoptotic insults are actually no longer needed for the 
reasons explained in the previous section. 
5. Conclusions 
The burden of cancer continues to increase, leading to pronounced morbidity and mortality in both 
developed and developing countries. Despite the efforts of academic institutions and pharmaceutical 
companies, the chemotherapeutic arsenal has remained limited, primarily due to the emergence of 
drug-resistant cancer types. Both terrestrial and marine natural sources have provided several lead 
compounds that have led to the development of the majority of the anticancer drugs currently used  
in therapeutics.  
Unlike marine macroorganisms, such as sponges and other sessile invertebrates, which have been 
extensively investigated, marine-derived fungi had been neglected until recently as a source of lead 
structures that could increase the clinical pipeline in chemotherapy research. Even so, growing 
numbers of marine-derived fungal secondary metabolites with interesting pharmacological activities 
that are considered valuable for the development of new chemotherapeutic agents have been reported 
over the last three decades. In this review, we have highlighted several marine-derived fungal 
metabolites that can modulate the activity of several key enzymes involved in tumor growth and 
metastasis, instead of having a limited pro-apoptotic effect. Because of their relevant and unconventional 
anticancer molecular mechanisms as well as their activity against MDR cancer cells, these metabolites 
are undoubtedly attractive as lead structures that should undergo further investigation, namely for the 
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synthesis of analogs that could increase their selectivity and reduce their toxicity. We thus believe that 
a given compound of interest that displays in vitro cytotoxic effects against cancer cells can be claimed 
as a potential anticancer agent if and only if it is selective towards normal cells and MDR cancer  
cells. As explained previously, this cytotoxic compound of interest should also induce non-apoptotic 
cell death.  
However, despite the identification of these promising candidates for pre-clinical development, it is 
expected that several additional lead structures will be discovered in the near future. The distinct 
biosynthetic capabilities of the marine-derived fungi as promoted by a distinct evolutionary pressure 
should be explored through a multidisciplinary approach in a way that increases the hit rate of novel 
lead structures with the potential to develop new anticancer drugs. Additional attempts should be 
undertaken to increase the contribution of obligate marine fungi as sources of new chemotherapeutic 
agents, as well as the systematic investigation of new marine fungal strains for which their biosynthetic 
potential has not yet been explored. An increased rate of discovery of novel lead compounds from 
marine fungi can also be achieved through new culturing techniques able to activate silent biogenetic 
gene clusters, leading to the production of distinct and unique metabolites that are not expressed under 
standard laboratory culturing conditions. These approaches include co-cultivation with either other 
fungal strains or bacteria, stress-inducing culturing methods and the OSMAC (One Strain Many 
Compounds) strategy. 
The recent dereplication of several metabolites with relevant anticancer properties originally 
reported from marine macroorganisms, the possibility of culturing marine-derived fungi through cheap 
fermentation techniques, and the untapped number of new marine-derived fungal species that have yet 
to be discovered clearly classify these microorganisms as one of the most promising sources for the 
discovery of new anticancer lead structures. 
The fact that there is still no single marine-derived fungal anticancer drug currently available on the 
market reflects the recent history of marine-derived fungi investigation for the discovery of new 
bioactive metabolites, as demonstrated in this review by their chemical diversity and promising 
anticancer properties. Thus, it would not be surprising if the current chemotherapeutic clinical pipeline 
were fed with marine-derived fungal agents in the near future.  
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